-
Aurisco Pharmaceutical Passes US FDA cGMP Inspection at Jiangsu Plant
•
China-based Aurisco Pharmaceutical (SHA: 605116) has announced the successful completion of a current Good Manufacturing Practice (cGMP) inspection by the US Food and Drug Administration (FDA) at its Active Pharmaceutical Ingredient (API) and finished dosage form (FDF) plant located in Yangzhou, Jiangsu province. The inspection confirmed that the site was…
-
Aurisco Partners with Cytiva to Build Oligonucleotide Production Plant
•
China-based contract development and manufacturing organization (CDMO) Aurisco Pharmaceutical Co., Ltd has revealed plans to establish its first commercial-scale production plant for oligonucleotides in partnership with US-based life sciences service provider Cytiva. The new plant, located in Yangzhou, Jiangsu Province, will utilize Cytiva’s Oligo FlexFactory platform and marks the first…
